research Y27632 Promotes Proliferation via EGFR Signaling in a Newly Isolated and Characterized Human Primary Sebocyte Cell Line
Y27632 increases cell growth through EGFR signaling, not ROCK1/2.
Search
for
Sort by
Research
30 / 740 resultsresearch Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution, And Tumor-Initiating Cells
Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.
research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
research Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Chemotherapy-Induced Iatrogenic Injury of Skin: New Drugs and New Concepts
New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
research Targeted Therapy in Melanoma
New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
research Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: The Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
research Skin Cancer: Understanding the Transformation from Conventional to Advanced Treatment Approaches
New treatments like nanotechnology show promise in improving skin cancer therapy.
research The PDGF/PDGFR Pathway as a Drug Target
The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
research Management of Toxicities of Targeted Therapies
Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
research Understanding, Recognizing, and Managing Toxicities of Targeted Anticancer Therapies
Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
research Keratosis Pilaris-Like Eruption During Chronic Myeloid Leukemia Treatment With Tyrosine Kinase Inhibitors: A Literature Review And Case Report On Imatinib
Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research RASopathic Skin Eruptions During Vemurafenib Therapy
Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
research Expression of Signaling Components in Embryonic Eyelid Epithelium
Eyelid cells share signaling components but differ in pathway activity.
research Eph Receptors and Ephrins: Therapeutic Opportunities
Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.
research Classification and Management of Skin, Hair, Nail, and Mucosal Side Effects of Epidermal Growth Factor Receptor Inhibitors
EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.
research Semiology of Skin Toxicity Associated with Epidermal Growth Factor Receptor Inhibitors
Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
research Erosive Pustular Dermatosis of the Scalp-Like Eruption Due to Gefitinib: Case Report and Review of Alopecia Associated with EGFR Inhibitors
Stopping gefitinib improved scalp condition in a woman with lung cancer.
research IL-36γ Drives Skin Toxicity Induced by EGFR/MEK Inhibition and Commensal Cutibacterium Acnes
A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.
research The Management of EGFR Inhibitor Adverse Events: A Case Series and Treatment Paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
research Rash from EGFR Inhibitors: Opportunities and Challenges for Palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research EGFR Controls Hair Shaft Differentiation in a p53-Independent Manner
EGFR helps control how hair grows and forms without needing p53 protein.
research Cutaneous Lymphadenoma Is a Distinct Trichoblastoma-like Lymphoepithelial Tumor With Diffuse Androgen Receptor Immunoreactivity, Notch1 Ligand in Reed-Sternberg-like Cells, and Common EGFR Somatic Mutations
Cutaneous Lymphadenoma is a unique skin tumor with specific protein markers and common gene mutations that may cause continuous cell growth.
research Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
research EGFR Marks a Subpopulation of Dermal Mesenchymal Cells Highly Expressing IGF1 Which Enhances Hair Follicle Regeneration
A certain type of skin cell, marked by EGFR, produces a lot of IGF1 and helps hair follicles grow back faster.